Most Read Articles
Roshini Claire Anthony, 24 Nov 2016

Moderate doses of celecoxib are noninferior to naproxen or ibuprofen in terms of cardiovascular (CV) safety, according to results of the PRECISION* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.

Roshini Claire Anthony, 28 Feb 2017

Recent neuropathic pain management guidelines have highlighted specific drugs to be used as first, second, and third line treatment of neuropathic pain, according to a presentation at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

Audrey Abella, 04 Apr 2017
Pregabalin did not significantly reduce symptoms of sciatica, including radiating posterolateral leg pain and back pain, compared with placebo, according to data from the PRECISE* trial.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.

Lutikizumab shows limited efficacy in knee osteoarthritis, synovitis

04 Feb 2019

Inhibition of interleukin (IL)-1 with lutikizumab falls short in the treatment of patients with knee osteoarthritis (OA), with the results of a phase II study showing that the drug yields limited reductions in pain without any improvement in synovitis.

Researchers randomized 350 patients with Kellgren‐Lawrence grade 2–3 knee OA and synovitis (determined by magnetic resonance imaging or ultrasound) to receive placebo or lutikizumab 25, 100 or 200 mg subcutaneously every 2 weeks for 50 weeks. Of these, 60 of 85 patients (70.6 percent) in the placebo group and 202 of 265 (76.2 percent) in the lutikizumab groups completed the study.

Primary endpoints were change from baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain index at week 16 and in magnetic resonance imaging (MRI) synovitis at week 26.

At week 16, WOMAC pain decreased significantly with lutikizumab 100 mg (p=0.050) but not with the 25- and 200-mg doses relative to placebo. WOMAC pain improved in all groups thereafter, although the change was not significantly different between lutikizumab and placebo.

Additionally, changes in MRI synovitis at week 26 and other key symptom‐ and most structure‐related endpoints at weeks 26 and 52 did not markedly differ across the treatment groups.

Injection site reactions, neutropaenia and discontinuations due to neutropenia occurred with greater frequency in the lutikizumab groups vs placebo group. Neutrophil counts and high‐sensitivity C‐reactive protein values decreased at all time points with lutikizumab 100 mg. Finally, immunogenic response exerted no meaningful effect on systemic lutikizumab concentrations.

The present data suggest that IL-1 inhibition is not an effective disease-modifying therapy in patients with knee OA, researchers said. More studies are needed to determine whether subgroups of knee OA patients might have symptomatic benefit from IL-1 inhibition.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 24 Nov 2016

Moderate doses of celecoxib are noninferior to naproxen or ibuprofen in terms of cardiovascular (CV) safety, according to results of the PRECISION* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.

Roshini Claire Anthony, 28 Feb 2017

Recent neuropathic pain management guidelines have highlighted specific drugs to be used as first, second, and third line treatment of neuropathic pain, according to a presentation at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

Audrey Abella, 04 Apr 2017
Pregabalin did not significantly reduce symptoms of sciatica, including radiating posterolateral leg pain and back pain, compared with placebo, according to data from the PRECISE* trial.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.